Literature DB >> 23749004

A longitudinal study of PSA and its influential factors in a cohort of Chinese men with initial PSA levels less than 4 ng ml(-1).

Ming Liu1, Jian-Ye Wang, Hong-Xue Su, Gang Wan, Ling Zhu, Xiao-Ming Wang.   

Abstract

To evaluate the longitudinal change in prostate-specific antigen (PSA) and the influence of initial PSA on the PSA change. We retrospectively analysed health examination data collected at Beijing Hospital from March 2007 to November 2011. Men with an initial PSA levels less than 4 ng ml(-1) and an annual PSA test for 5 years were enrolled into the study. The men were separated into four groups by the initial PSA level (0-0.99, 1-1.99, 2-2.99 and 3-3.99 ng ml(-1)), and the difference in PSA change among the four groups was analysed. A total of 1330 men were enrolled into the study. The mean age, initial PSA and PSA velocity (PSAV) were 58.17 ± 14.63 (range 24-91) years, 1.18 ± 0.79 (range 0-4) ng ml(-1) and 0.04 ± 0.25 (range -1.34-2.02) ng ml(-1) year(-1). Pearson's correlation analysis showed no correlation between initial PSA and PSAV (r=-0.036, P=0.189). The PSAV of the 0-0.99, 1-1.99, 2-2.99 and 3-3.99 ng ml(-1) initial PSA groups was 0.03 ± 0.11, 0.07 ± 0.32, 0.03 ± 0.34 and -0.01 ± 0.43 ng ml(-1) year(-1), respectively (P=0.06). As the initial PSA increased, the percentage of having a PSAV over 0.75 ng ml(-1) year(-1) and a negative PSAV both significantly increased. Males with a baseline PSA of 0-0.99, 1-1.99, 2-2.99 and 3-3.99 ng ml(-1) had a 1.88%, 6.16%, 16.30% and 57.81% chance, respectively, that their PSA would increase above 4.0 ng ml(-1) over the following 4 years (P<0.0001). The PSAV has no correlation with the initial PSA level. However, as the initial PSA increases, the chance that males will have an abnormal PSA or PSAV in the future increases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23749004      PMCID: PMC3739242          DOI: 10.1038/aja.2013.41

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  17 in total

1.  Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer.

Authors:  Kazuto Ito; Takumi Yamamoto; Masaru Ohi; Hiroyuki Takechi; Kohei Kurokawa; Kazuhiro Suzuki; Hidetoshi Yamanaka
Journal:  Int J Cancer       Date:  2004-04-10       Impact factor: 7.396

2.  Impact of race and baseline PSA on longitudinal PSA.

Authors:  Katharine McGreevy; Keith Rodgers; Stuart Lipsitz; Nabil Bissada; David Hoel
Journal:  Int J Cancer       Date:  2006-04-01       Impact factor: 7.396

3.  Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.

Authors:  Andreas P Berger; Martina Deibl; Hannes Steiner; Jasmin Bektic; Alexandre Pelzer; Robert Spranger; Helmut Klocker; Georg Bartsch; Wolfgang Horninger
Journal:  Prostate       Date:  2005-08-01       Impact factor: 4.104

4.  Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging.

Authors:  Stacy Loeb; H Ballentine Carter; Edward M Schaeffer; Anna Kettermann; Luigi Ferrucci; E Jeffrey Metter
Journal:  Urology       Date:  2011-01       Impact factor: 2.649

5.  Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.

Authors:  H Ballentine Carter; Luigi Ferrucci; Anna Kettermann; Patricia Landis; E James Wright; Jonathan I Epstein; Bruce J Trock; E Jeffrey Metter
Journal:  J Natl Cancer Inst       Date:  2006-11-01       Impact factor: 13.506

6.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Kimberly A Roehl; William J Catalona
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

7.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

Authors:  H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

8.  The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/ml or less.

Authors:  Kazuto Ito; Takumi Yamamoto; Kazuhiro Suzuki; Kohei Kurokawa; Hidetoshi Yamanaka
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

9.  Usefulness of prostate-specific antigen velocity in screening for prostate cancer.

Authors:  Kazuto Ito; Takumi Yamamoto; Masaru Ohi; Yutaka Kubota; Yoshitatsu Fukabori; Kohei Kurokawa; Kazuhiro Suzuki; Hidetoshi Yamanaka
Journal:  Int J Urol       Date:  2002-06       Impact factor: 3.369

10.  Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project.

Authors:  C Mettlin; P J Littrup; R A Kane; G P Murphy; F Lee; A Chesley; R Badalament; F K Mostofi
Journal:  Cancer       Date:  1994-09-01       Impact factor: 6.860

View more
  1 in total

1.  The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Azza Shoaibi; Gowtham A Rao; Bo Cai; John Rawl; James R Hébert
Journal:  Ann Epidemiol       Date:  2015-10-28       Impact factor: 3.797

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.